220349-80-4

Basic information

• Product Name: Cyclopropanamine, 2-(4-fluorophenyl)-, (1R,2S)- (9CI)
• Synonyms: Cyclopropanamine, 2-(4-fluorophenyl)-, (1R,2S)- (9CI);(1R,2S)-2-(4-fluorophenyl)cyclopropanaMine;2-(4-fluorophenyl)cyclopropanamine;(1R,2S)- (9CI)2-(4-fluorophenyl)-, Cyclopropanamine;(1R,2S)-2-(4-Fluoro-phenyl)-cyclopropylamine;(1R,2S)-2-(4-fluorophenyl)cyclopropan-1-amine
• CAS NO: 220349-80-4
• Molecular Formula: C9H10FN
• Molecular Weight: 151.1808032
• Product Categories: HALIDE
• Mol File: 220349-80-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Cyclopropanamine, 2-(4-fluorophenyl)-, (1R,2S)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopropanamine, 2-(4-fluorophenyl)-, (1R,2S)- (9CI)(220349-80-4)
• EPA Substance Registry System: Cyclopropanamine, 2-(4-fluorophenyl)-, (1R,2S)- (9CI)(220349-80-4)

Safety Data

• Hazardous Substances Data: 220349-80-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Cyclopropanamine, 2-(4-fluorophenyl)-, (1R,2S)(9CI) is used as an impurity in the production of Ticagrelor (T437700) for [application reason] its presence in the final product may affect the safety, efficacy, and quality of the medication. The control and monitoring of this impurity are essential to ensure the overall quality of Ticagrelor and its therapeutic benefits.

Upstream product

• 210422-66-5 4-fluorobenzaldehyde p-toluenesulfonylhydrazone 
• 459-57-4 4-fluorobenzaldehyde 
• 107633-40-9 4-fluorophenyl benzaldehyde-tosylhydrazone sodium salt 
• 1314324-00-9 (1R,2S)-2-(4-fluorophenyl)cyclopropan-1-amine hydrochloride 
• 1314323-96-0 (1R,2S)-tert-butyl 2-(4-fluorophenyl)cyclopropylcarbamate 
• 515179-19-8 2-(4-fluorophenyl)cyclopropanecarboxylic acid 
• 893751-08-1 methyl 2-(4-fluorophenyl)cyclopropane-1-carboxylate 
• 459-32-5 (E)-4-fluorocinnamic acid 
• 96426-60-7 methyl (2E)-3-(4-fluorophenyl)-2-propenoate 
• 161711-27-9 (1R,2R)-2-(4-fluorophenyl)cyclopropanecarboxylic acid 

Relevant articles and documents

METHODS AND PROCESSES FOR THE PREPARATION OF KDM1A INHIBITORS

Provided in this disclosure are methods for the synthesis of substituted 2-arylcyclopropylamines and 2-heteroarylcyclopropylamines and related compounds. Also provided are methods for reduction of thioesters to aldehydes, and methods for reductive animation of cyclopropylamines.

CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS

The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.

C-H activation enables a rapid structure-activity relationship study of arylcyclopropyl amines for potent and selective LSD1 inhibitors

We describe the structure-activity relationship of various arylcyclopropylamines (ACPAs), which are potent LSD1 inhibitors. More than 45 ACPAs were synthesized rapidly by an unconventional method that we have recently developed, consisting of a C-H borylation and cross-coupling sequence starting from cyclopropylamine. We also generated NCD38 derivatives, which are known as LSD1 selective inhibitors, and discovered a more effective inhibitor compared to the original NCD38.

NOVEL COMPOUNDS

Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides.

KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDMIA, and methods of increasing gamma globin gene expression in a human or animal subject are also provided for the treatment diseases such as sickle cell disease.

NOVEL COMPOUNDS

Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides.

Triazolo(4,5-d)pyrimidine compounds

Triazolo[4,5-d]pyrimidine compounds are provided of the formula (I) wherein R1, R2, R3, R4, R5and R6are as defined in the specification. Compositions containing the compounds are also provided, together with processes for their preparation and methods of use in the treatment of diseases, including myocardial infarction and unstable angina.